Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616239 · ClinicalTrials.gov registry record · Phase 4
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
A Phase 4 study of Melasma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00616239: Completed Phase 4 study of Melasma, sponsored by University of Texas Southwestern Medical Center.
NCT00616239 is a Phase 4 study of Melasma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616239, a Phase 4 study of Melasma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll 20 adult Hispanic women. Participants will apply 4% hydroquinone cream twice daily to affected areas on the face for 14 weeks and half the face will be peeled with 20-30% salicylic acid every two weeks for a total of 4 peels. The first two peels will be 20% salicylic acid and the second two peels will be with 30% salicylic acid. The purpose of the study will be to evaluate the safety and efficacy of salicylic acid combined with 4% hydroquinone versus 4% hydroquinone alone.
Primary Outcome
Improvement of melasma on the peel side using mexameter reading
Conditions Studied
Interventions
- DRUG 20-30% Salicylic Acid peels to the right side of the face
- DRUG 20-30% Salicylic Acid peels to the left side of the face
Study Locations (1)
Texas
- UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-01 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
What the finished NCT00616239 record still lists
NCT00616239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 2 interventions - of which 20-30% Salicylic Acid peels to the right side of the face is the first listed.
NCT00616239 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00616239 about?
NCT00616239 is a clinical study titled "Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women". This study will enroll 20 adult Hispanic women. Participants will apply 4% hydroquinone cream twice daily to affected areas on the face for 14 weeks and half the face will be peeled with 20-30% salicylic acid every two weeks for a total of 4 peels. The first two peels will be 20% salicylic acid and ...
What is the current status of trial NCT00616239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2008-01. Estimated completion is 2018-03.
What conditions does trial NCT00616239 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT00616239?
The interventions under investigation include: 20-30% Salicylic Acid peels to the right side of the face (DRUG), 20-30% Salicylic Acid peels to the left side of the face (DRUG).
Who is sponsoring clinical trial NCT00616239?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616239 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00616239's enrollment target sits among peer trials
20 4th of 8 higher than 4 of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of an Herbal-Based De-Pigmenting System
COMPLETED · Phase 4
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia